These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3622311)

  • 41. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine.
    Mastrosimone F; Iaccarino C; de Caterina G
    J Med; 1992; 23(1):1-16. PubMed ID: 1573338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 43. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Preliminary report.
    Schaffler K; Hörmann E; Arnold H
    Arzneimittelforschung; 1981; 31(6):1032-5. PubMed ID: 7196236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
    Diener HC; Krupp P; Schmitt T; Steitz G; Milde K; Freytag S
    Cephalalgia; 2001 Feb; 21(1):66-70. PubMed ID: 11298666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease.
    Fine EW; Lewis D; Villa-Landa I; Blakemore CB
    Br J Psychiatry; 1970 Aug; 117(537):157-61. PubMed ID: 4921174
    [No Abstract]   [Full Text] [Related]  

  • 46. Organizational and visual memory deficits in schizophrenia and bipolar psychoses using the Rey-Osterrieth complex figure: effects of duration of illness.
    Seidman LJ; Lanca M; Kremen WS; Faraone SV; Tsuang MT
    J Clin Exp Neuropsychol; 2003 Oct; 25(7):949-64. PubMed ID: 13680442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of cyclandelate on psychological test performance in patients with cerebral vascular insufficiency.
    Smith WL; Lowrey JB; Davis JA
    Curr Ther Res Clin Exp; 1968 Dec; 10(12):613-8. PubMed ID: 4972756
    [No Abstract]   [Full Text] [Related]  

  • 48. Influence of cyclandelate on in vitro red blood cell deformability.
    Hall DW; van den Hoven WE
    Drugs; 1987; 33 Suppl 2():30-40. PubMed ID: 3622306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of food on the bioavailability of cyclandelate from commercial capsules.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imazato Y
    Clin Pharmacol Ther; 1991 Jun; 49(6):641-7. PubMed ID: 2060253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group.
    Diener HC; Föh M; Iaccarino C; Wessely P; Isler H; Strenge H; Fischer M; Wedekind W; Taneri Z
    Cephalalgia; 1996 Oct; 16(6):441-7. PubMed ID: 8902255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Stability of cyclandelate in a soft capsule].
    Richard J; Andermann G
    Pharm Acta Helv; 1982; 57(4):116-21. PubMed ID: 7089017
    [No Abstract]   [Full Text] [Related]  

  • 52. Fibrinolytic activity of oral cyclandelate in patients with generalized atherosclerotic vasculopathy: a double-blind study.
    Forconi S; Cappelli R; Guerrini M; Frigerio C; Messa GL; Furesi L
    J Int Med Res; 1990; 18(4):257-65. PubMed ID: 2121564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of cyclandelate in chronic brain syndrome with arteriosclerosis.
    Fine EW
    Curr Ther Res Clin Exp; 1971 Sep; 13(9):568-74. PubMed ID: 5000458
    [No Abstract]   [Full Text] [Related]  

  • 54. Cyclandelate. An inhibitor of cholesterol esterification.
    Middleton B; Cacciaguerra F; White D
    Drugs; 1987; 33 Suppl 2():75-9. PubMed ID: 3622309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy.
    Brown ES; Stuard G; Liggin JD; Hukovic N; Frol A; Dhanani N; Khan DA; Jeffress J; Larkin GL; McEwen BS; Rosenblatt R; Mageto Y; Hanczyc M; Cullum CM
    Biol Psychiatry; 2005 Mar; 57(5):543-8. PubMed ID: 15737670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 57. A preliminary study of the effects of cyclandelate.
    Davies G
    Med J Aust; 1971 Feb; 1(6):313-7. PubMed ID: 4925923
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of human platelet functions by cyclandelate.
    van den Hoven WE; Hall DW
    Drugs; 1987; 33 Suppl 2():41-52. PubMed ID: 3304954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benefits of cyclandelate in the treatment of disorders of ageing.
    Le Poncin-Lafitte M
    Br J Clin Pract Suppl; 1984; 34():58-61. PubMed ID: 6430325
    [No Abstract]   [Full Text] [Related]  

  • 60. Cyclandelate as a calcium modulating agent in rat cerebral cortex.
    Bast A; Leurs R; Timmerman H
    Drugs; 1987; 33 Suppl 2():67-74. PubMed ID: 3040372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.